North America currently maintains a dominant position in the genetic therapeutics sector, primarily due to the concentration of major pharmaceutical headquarters and elite research universities in the United States and Canada. The region benefits from a robust ecosystem of clinical trial sites and a high level of patient awareness regarding immunotherapy. However, Europe is a close...